Published 19 March 2009, doi:10.1136/bmj.b825
Cite this as: BMJ 2009;338:b825

Research

Cost effectiveness analysis of larval therapy for leg ulcers

¹ Department of Health Sciences, University of York, York YO10 5DD, ² School of Healthcare, University of Leeds, UK

Objective To assess the cost effectiveness of larval therapy compared with hydrogel in the management of leg ulcers.

Design Cost effectiveness and cost utility analyses carried out alongside a pragmatic multicentre, randomised, open trial with equal randomisation.

Population Intention to treat population comprising 267 patients with a venous or mixed venous and arterial ulcers with at least 25% coverage of slough or necrotic tissue.

Interventions Patients were randomly allocated to debridement with bagged larvae, loose larvae, or hydrogel.

Main outcome measure The time horizon was 12 months and costs were estimated from the UK National Health Service perspective. Cost effectiveness outcomes are expressed in terms of incremental costs per ulcer-free day (cost effectiveness analysis) and incremental costs per quality adjusted life years (cost utility analysis).

Results The larvae arms were pooled for the main analysis. Treatment with larval therapy cost, on average, £96.70 (109.61; $140.57) more per participant per year (95% confidence interval –£491.9 to £685.8) than treatment with hydrogel. Participants treated with larval therapy healed, on average, 2.42 days before those in the hydrogel arm (95% confidence interval –0.95 to 31.91 days) and had a slightly better health related quality of life, as the annual difference in QALYs was 0.011 (95% confidence interval –0.067 to 0.071). However, none of these differences was statistically significant. The incremental cost effectiveness ratio for the base case analysis was estimated at £8826 per QALY gained and £40 per ulcer-free day. Considerable uncertainty surrounds the outcome estimates.

Conclusions Debridement of sloughy or necrotic leg ulcers with larval therapy is likely to produce similar health benefits and have similar costs to treatment with hydrogel.

Trial registration Current Controlled Trials ISRCTN55114812 [controlled-trials.com] and National Research Register N0484123692.

© Soares et al 2009
This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    StumbleUpon    Technorati    What's this?

Relevant Articles

Study authors respond to points in editorial

Nicky Cullum, Martin Bland, Jo Dumville, Cynthia Iglesias, Susan O’Meara, Marta Soares, David Torgerson, Andrea Nelson, and Gill Worthy
BMJ 2009 338: b2098. [Extract] [Full Text]

How to measure success in treating chronic leg ulcers

Joseph E Grey, David Leaper, and Keith Harding
BMJ 2009 338: b1434. [Extract] [Full Text]

Larval therapy for leg ulcers (VenUS II): randomised controlled trial

Jo C Dumville, Gill Worthy, J Martin Bland, Nicky Cullum, Christopher Dowson, Cynthia Iglesias, Joanne L Mitchell, E Andrea Nelson, Marta O Soares, David J Torgerson on behalf of the VenUS II team
BMJ 2009 338: b773. [Abstract] [Full Text] [PDF]

Analysis of serial measurements in medical research.

J N Matthews, D G Altman, M J Campbell, and P Royston
BMJ 1990 300: 230-235. [Abstract] [PDF]

Chronic ulceration of the leg: extent of the problem and provision of care.

M J Callam, C V Ruckley, D R Harper, and J J Dale
Br Med J (Clin Res Ed) 1985 290: 1855-1856. [Abstract] [PDF]

This article has been cited by other articles:

• Cullum, N., Bland, M., Dumville, J., Iglesias, C., O'Meara, S., Soares, M., Torgerson, D., Nelson, A., Worthy, G. (2009). Study authors respond to points in editorial. BMJ 338: b2098-b2098 [Full text]  
• (2009). Making Your Skin Crawl Does Not Heal Ulcers Faster. Journal Watch Dermatology 2009: 5-5 [Full text]  
• Grey, J. E, Leaper, D., Harding, K. (2009). How to measure success in treating chronic leg ulcers. BMJ 338: b1434-b1434 [Full text]  
• Dumville, J. C, Worthy, G., Bland, J M., Cullum, N., Dowson, C., Iglesias, C., Mitchell, J. L, Nelson, E A., Soares, M. O, Torgerson, D. J, on behalf of the VenUS II team, (2009). Larval therapy for leg ulcers (VenUS II): randomised controlled trial. BMJ 338: b773-b773 [Abstract] [Full text]  

Online poll

Find out more on doc2doc >>